Fate Therapeutics, Inc. (NASDAQ:FATE) has a beta value of 1.75 and has seen 675,372 shares traded in the last trading session. The company, currently valued at $4.59 Billion, closed the last trade at $52.65 per share which meant it gained $2.94 on the day or 5.91% during that session. The FATE stock price is -3.76% off its 52-week high price of $54.63 and 74.81% above the 52-week low of $13.26. If we look at the company’s 10-day average daily trading volume, we find that it stood at 647.9 Million shares traded. The 3-month trading volume is 874.5 Million shares.
The consensus among analysts is that Fate Therapeutics, Inc. (FATE) is a Buy stock at the moment, with a recommendation rating of 1.7. None of the analysts rate the stock as a Sell, while none rate it as Overweight. 2 out of 13 have rated it as a Hold, with 11 advising it as a Buy. None have rated the stock as Underweight. The expected earnings per share for the stock is -$0.38.
Fate Therapeutics, Inc. (NASDAQ:FATE) trade information
Sporting 5.91% in the green today, the stock has traded in the green over the last five days, with the highest price hit on Wednesday, Nov 18 when the FATE stock price touched $53.42- or saw a rise of 1.44%. Year-to-date, Fate Therapeutics, Inc. shares have moved 169.03%, while the 5-day performance has seen it change 4.24%. Over the past 30 days, the shares of Fate Therapeutics, Inc. (NASDAQ:FATE) have changed 9.26%. Short interest in the company has seen 14.35 Million shares shorted with days to cover at 0.02.
Wall Street analysts have a consensus price target for the stock at $53.54, which means that the shares’ value could jump 1.69% from current levels. The projected low price target is $30 while the price target rests at a high of $71. In that case, then, we find that the current price level is +34.85% off the targeted high while a plunge would see the stock lose -43.02% from current levels.
Fate Therapeutics, Inc. (FATE) estimates and forecasts
Figures show that Fate Therapeutics, Inc. shares have outperformed across the wider relevant industry. The company’s shares have gained +55.82% over the past 6 months, with this year growth rate of 29.86%, compared to 14.5% for the industry. Other than that, the company has, however, lowered its growth outlook for the 2020 fiscal year revenue. Growth estimates for the current quarter are -2.7% and 6.8% for the next quarter. Revenue growth from the last financial year stood is estimated to be +92.3%.
11 analysts offering their estimates for the company have set an average revenue estimate of $5.21 Million for the current quarter. 9 have an estimated revenue figure of $5.03 Million for the next quarter concluding in March 01, 2021. Year-ago sales stood $2.8 Million and $2.52 Million respectively for this quarter and the next, and analysts expect sales will grow by 85.9% for the current quarter and 100% for the next.
If we evaluate the company’s growth over the last 5-year and for the next 5-year period, we find that annual earnings growth was -2.6% over the past 5 years. Earnings growth for 2020 is a modest -21.5%.
Fate Therapeutics, Inc. (NASDAQ:FATE)’s Major holders
Insiders own 1.79% of the company shares, while shares held by institutions stand at 101.37% with a share float percentage of 103.22%. Investors are also buoyed by the number of investors in a company, with Fate Therapeutics, Inc. having a total of 302 institutions that hold shares in the company. The top two institutional holders are Redmile Group, LLC with over 12.63 Million shares worth more than $504.81 Million. As of September 29, 2020, Redmile Group, LLC held 14.48% of shares outstanding.
The other major institutional holder is FMR, LLC, with the holding of over 6.97 Million shares as of September 29, 2020. The firm’s total holdings are worth over $278.65 Million and represent 7.99% of shares outstanding.
Also the top two Mutual Funds that are holding company’s shares are Fidelity Growth Company Fund and Vanguard Total Stock Market Index Fund. As of August 30, 2020, the former fund manager holds about 2.54% shares in the company for having 2218765 shares of worth $80.76 Million while later fund manager owns 2.05 Million shares of worth $70.24 Million as of June 29, 2020, which makes it owner of about 2.35% of company’s outstanding stock.